(-0.86%) 5 028.11 points
(-1.22%) 37 990 points
(-1.18%) 15 527 points
(-0.01%) $82.80
(-1.81%) $1.623
(0.03%) $2 339.10
(0.06%) $27.36
(0.72%) $922.40
(-0.30%) $0.932
(-0.11%) $10.97
(-0.43%) $0.799
(-0.06%) $92.27
Live Chart Being Loaded With Signals
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases...
Stats | |
---|---|
Today's Volume | 7.88M |
Average Volume | 9.62M |
Market Cap | 62.55B |
EPS | HKD0 ( 2024-03-25 ) |
Next earnings date | ( HKD0 ) 2024-06-20 |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -54.30 |
ATR14 | HKD0.0460 (0.12%) |
Volume Correlation
Innovent Biologics Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Innovent Biologics Inc Correlation - Currency/Commodity
Innovent Biologics Inc Financials
Annual | 2023 |
Revenue: | HKD6.21B |
Gross Profit: | HKD4.40B (70.89 %) |
EPS: | HKD-0.660 |
Q4 | 2023 |
Revenue: | HKD1.75B |
Gross Profit: | HKD1.24B (70.75 %) |
EPS: | HKD-0.280 |
Q3 | 2023 |
Revenue: | HKD1.75B |
Gross Profit: | HKD1.24B (70.75 %) |
EPS: | HKD-0.280 |
Q2 | 2023 |
Revenue: | HKD1.35B |
Gross Profit: | HKD959.89M (71.06 %) |
EPS: | HKD-0.0453 |
Financial Reports:
No articles found.
Innovent Biologics Inc
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators